Washington: Currently, large doses of chemotherapy are required when treating certain forms of cancer, resulting in toxic side effects. The chemicals enter the body and work to destroy or shrink the tumour, but also harm vital organs and drastically affect bodily functions. Now, University of Missouri scientists have found a more efficient way of targeting prostate tumours by using gold nanoparticles and a compound found in tea leaves. This new treatment would require doses that are thousands of times smaller than chemotherapy and do not travel through the body inflicting damage to healthy areas. The study is published in the Proceedings of the National Academy of Sciences.
“In our study, we found that a special compound in tea was attracted to tumour cells in the prostate,” says Kattesh Katti, curators’ professor of radiology and physics in the School of Medicine and the College of Arts and Science and senior research scientist at the MU Research Reactor. “When we combined the tea compound with radioactive gold nanoparticles, the tea compound helped ‘deliver’ the nanoparticles to the site of the tumours and the nanoparticles destroyed the tumour cells very efficiently.”
Currently, doctors treat prostate cancer by injecting hundreds of radioactive ‘seeds’ into the prostate. However, that treatment is not effective when treating an aggressive form of prostate cancer, says Cathy Cutler, research professor at the MU Research Reactor and co-author of the study. The size of the seeds and their inability to deliver effective doses hampers their ability to stop the aggressive form of prostate cancer.
In the study, the MU scientists created nanoparticles that are just the right size. Instead of hundreds of injections, the team only used one or two injections, and the nanoparticles were more likely to stay very close to the tumour sites.
Cutler and Katti have been working with colleagues Raghuraman Kannan, Anandhi Upendran, Charles Caldwell as well as others in the Department of Radiology and at the MU Research Reactor to develop and design the nanoparticles to the correct shape and size to treat prostate cancer. If the nanoparticles produced are too small, they can escape and spread; if they are made large enough, the nanoparticles will stay inside the tumour and treat it much more effectively than current methods.
“Current therapy for this disease is not effective in those patients who have aggressive prostate cancer tumours,” Cutler says. “Most of the time, prostate cancers are slow-growing; the disease remains localized and it is easily managed. Aggressive forms of the disease spread to other parts of the body, and it is the second-leading cause of cancer deaths in US men. However, we believe the gold nanoparticles could shrink the tumours, both those that are slow-growing and aggressive, or eliminate them completely.”
“This treatment is successful due to the inherent properties of radioactive gold nanoparticles,” Kannan says. “First, the gold nanoparticles should be made to the correct size, and second, they have very favourable radiochemical properties, including a very short half-life.”
With a half-life of only 2.7 days, the radioactivity from the gold nanoparticles is finished within three weeks.
“Because of their size and the compound found in tea, the nanoparticles remain at the tumour sites,” Upendran says. “This helps the nanoparticles maintain a high level of effectiveness, resulting in significant tumour volume reduction within 28 days of treatment.”
In the current study, the team tested the nanoparticles on mice. Prior to human trials, the scientists will study the treatment in dogs with prostate cancer. Prostate cancer in dogs is extremely close to the human form of the disease.
“When it comes to drug discovery, MU is fortunate because we have a combination of experts in cancer research, animal modelling, isotope production and nanomedicine, and state-of-the-art research infrastructure to take discoveries from ‘the bench to the bedside’ and never leave campus,” Katti says. “For example, we developed the nanoparticles here at our research reactor, which is one of the few places in the world that produces therapeutic, clinical grade radioisotopes. We then tested the radioactive gold nanoparticles in small animals in collaboration with other radiology researchers using testing facilities located at the Harry S Truman Veterans Hospital. Our next steps include partnering with the College of Veterinary Medicine to treat larger animals with the hopes of having human clinical trials, held on our campus, soon.”
Katti, Cutler, Kannan, Upendran and Caldwell were joined in the study by Ravi Shukla, Nripen Chanda and Ajit Zambre, all from the Department of Radiology.